Veradigm (MDRX) 10-Q 5 May 17 2017 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2017	Apr. 28, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q1
Trading Symbol	MDRX
Entity Registrant Name	ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.
Entity Central Index Key	1,124,804
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		181,464,603

CONSOLIDATED BALANCE SHEETS (Un

CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Current assets:
Cash and cash equivalents	$ 104,391	$ 96,610
Accounts receivable, net of allowance of $35,260 and $32,670 as of March 31, 2017 and December 31, 2016, respectively	414,613	405,172
Prepaid expenses and other current assets	108,157	102,551
Total current assets	627,161	604,333
Available for sale marketable securities	74,400	149,100
Fixed assets, net	153,197	148,810
Software development costs, net	175,371	163,879
Intangible assets, net	720,417	741,403
Goodwill	1,928,358	1,924,052
Deferred taxes, net	3,031	2,791
Other assets	117,083	97,791
Total assets	3,799,018	3,832,159
Current liabilities:
Accounts payable	131,149	126,144
Accrued expenses	69,496	86,135
Accrued compensation and benefits	55,231	64,291
Deferred revenue	412,620	363,772
Current maturities of long-term debt	18,277	15,158
Non-recourse current maturities of long-term debt - Netsmart	2,456	2,451
Current maturities of capital lease obligations	9,159	9,126
Total current liabilities	698,388	667,077
Long-term debt	712,676	717,853
Non-recourse long-term debt - Netsmart	576,673	576,918
Long-term capital lease obligations	8,696	9,877
Deferred revenue	18,008	18,009
Deferred taxes, net	140,040	141,752
Other liabilities	56,913	39,787
Total liabilities	2,211,394	2,171,273
Redeemable convertible non-controlling interest - Netsmart	398,648	387,685
Commitments and contingencies
Stockholders’ equity:
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of March 31, 2017 and December 31, 2016	0	0
Common stock: $0.01 par value, 349,000 shares authorized as of March 31, 2017 and December 31, 2016; 268,951 and 181,464 shares issued and outstanding as of March 31, 2017, respectively; 267,997 and 180,510 shares issued and outstanding as of December 31, 2016, respectively	2,690	2,680
Treasury stock: at cost, 87,487 shares as of March 31, 2017 and December 31, 2016	(310,993)	(310,993)
Additional paid-in capital	1,784,801	1,789,959
Accumulated deficit	(194,521)	(187,351)
Accumulated other comprehensive loss	(134,189)	(61,829)
Total Allscripts Healthcare Solutions, Inc.'s stockholders' equity	1,147,788	1,232,466
Non-controlling interest	41,188	40,735
Total stockholders’ equity	1,188,976	1,273,201
Total liabilities and stockholders’ equity	$ 3,799,018	$ 3,832,159

CONSOLIDATED BALANCE SHEETS (U3

CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance	$ 35,260	$ 32,670
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	349,000,000	349,000,000
Common stock, shares issued	268,951,000	267,997,000
Common stock, shares outstanding	181,464,000	180,510,000
Treasury stock at cost, shares	87,487,000	87,487,000

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Revenue:
Software delivery, support and maintenance	$ 272,458	$ 229,158
Client services	141,017	116,400
Total revenue	413,475	345,558
Cost of revenue:
Software delivery, support and maintenance	83,397	75,169
Client services	124,939	100,859
Amortization of software development and acquisition-related assets	26,487	17,632
Total cost of revenue	234,823	193,660
Gross profit	178,652	151,898
Selling, general and administrative expenses	110,845	84,153
Research and development	49,232	47,037
Asset impairment charges	0	4,650
Amortization of intangible and acquisition-related assets	7,312	4,162
Income from operations	11,263	11,896
Interest expense	(20,180)	(6,969)
Other income, net	239	366
Equity in net income (loss) of unconsolidated investments	285	(2,603)
(Loss) income before income taxes	(8,393)	2,690
Income tax provision	(172)	(563)
Net (loss) income	(8,565)	2,127
Less: Net income attributable to non-controlling interests	(453)	(78)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	0
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (19,980)	$ 2,049
(Loss) earnings per share - basic attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.11)	$ 0.01
(Loss) earnings per share - diluted attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (0.11)	$ 0.01

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (8,565)	$ 2,127
Other comprehensive income (loss):
Foreign currency translation adjustments	1,515	744
Change in unrealized (loss) gain on available for sale securities	(74,702)	0
Change in fair value of derivatives qualifying as cash flow hedges	1,348	441
Other comprehensive (loss) income before income tax expense	(71,839)	1,185
Income tax expense related to items in other comprehensive loss	(521)	(174)
Total other comprehensive (loss) income	(72,360)	1,011
Comprehensive (loss) income	(80,925)	3,138
Less: Comprehensive income attributable to non-controlling interests	(453)	(78)
Comprehensive (loss) income, net	$ (81,378)	$ 3,060

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Cash flows from operating activities:
Net (loss) income	$ (8,565)	$ 2,127
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	49,694	34,452
Stock-based compensation expense	7,946	9,919
Excess tax benefits from stock-based compensation	0	(197)
Deferred taxes	(1,570)	(362)
Asset impairment charges	0	4,650
Equity in net (income) loss of unconsolidated investments	(285)	2,603
Other losses, net	1,240	456
Changes in operating assets and liabilities (net of businesses acquired):
Accounts receivable, net	(8,010)	(12,250)
Prepaid expenses and other assets	(4,464)	(1,815)
Accounts payable	2,869	16,997
Accrued expenses	(5,567)	(5,165)
Accrued compensation and benefits	(5,501)	(24,929)
Deferred revenue	48,687	49,393
Other liabilities	(997)	54
Net cash provided by operating activities	75,477	75,933
Cash flows from investing activities:
Capital expenditures	(14,524)	(7,752)
Capitalized software	(34,011)	(15,134)
Cash paid for business acquisitions, net of cash acquired	(3,975)	0
Purchases of equity securities, other investments and related intangible assets	0	(500)
Proceeds received from sale of fixed assets	0	11
Net cash used in investing activities	(52,510)	(23,375)
Cash flows from financing activities:
Proceeds from sale or issuance of common stock	0	5
Excess tax benefits from stock-based compensation	0	197
Taxes paid related to net share settlement of equity awards	(5,864)	(4,146)
Payments of capital lease obligations	(3,015)	(239)
Credit facility payments	(86,726)	(28,164)
Credit facility borrowings, net of issuance costs	80,000	0
Repurchase of common stock	0	(37,517)
Net cash used in financing activities	(15,605)	(69,864)
Effect of exchange rate changes on cash and cash equivalents	419	549
Net increase (decrease) in cash and cash equivalents	7,781	(16,757)
Cash and cash equivalents, beginning of period	96,610	116,873
Cash and cash equivalents, end of period	104,391	100,116
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest in Netsmart	10,962	0
Obligations to enter into capital leases	$ 1,407	$ 0

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Basis of Presentation and Significant Accounting Policies	1. Basis of Presentation and Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated. Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”). Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates. Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K. Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). We currently plan to adopt the standard effective January 1, 2018 using the full retrospective method. We have completed our initial assessment of our systems, data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware, software-as-a-service-based offerings, professional services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscriptions that include both software licenses and software maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue recognition treatment required under the standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations

Business Combinations	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Business Combinations	2. Business Combinations 2017 Business Combinations Asset Purchase Agreement with Third Party On March 31, 2017, Netsmart (as defined below) entered into an Asset Purchase Agreement with a third party, for an aggregate cash consideration of $4.0 million to acquire intellectual property, certain contractual relationships and certain associates. This transaction will be accounted for as a business combination. The preliminary allocation of the fair value of the consideration transferred has not been completed given the timing of this transaction. This purchase expands Netsmart’s presence in its current markets. 2016 Business Combinations Update Formation of Joint Business Entity and Acquisition of Netsmart, Inc. On March 20, 2016, we entered into a Contribution and Investment Agreement with GI Netsmart Holdings LLC, a Delaware limited liability company (“GI Partners”), to form a joint business entity to which we contributed our Homecare TM TM Acquisition of HealthMEDX On October 27, 2016, Netsmart completed the acquisition of HealthMEDX, LLC, a Delaware limited liability company (“HealthMEDX”), for an aggregate consideration of $39.2 million. HealthMEDX is a provider of electronic medical record solutions for long-term and post-acute care including continuing care retirement communities, assisted living, independent living, skilled nursing and home care providers. During the three months ended March 31, 2017, we finalized the allocation of the fair value of the consideration transferred and recorded a measurement period adjustment of $0.1 million related to the fair value of liabilities with an offset in the residual allocation to goodwill. Supplemental Information The supplemental pro forma results below for the three months ended March 31, 2016 were calculated after applying our accounting policies and adjusting the results of Netsmart and HealthMEDX to reflect (i) the additional depreciation and amortization that would have been charged resulting from the fair value adjustments to property, plant and equipment and intangible assets, (ii) the additional interest expense associated with Netsmart’s borrowings under new term loans and (iii) the additional amortization of the estimated adjustment to decrease the assumed deferred revenue obligations to fair value that would have been charged assuming both acquisitions occurred on January 1, 2015, together with the consequential tax effects. The supplemental pro forma results were also adjusted to exclude acquisition-related and transaction costs incurred during this period. The effects of transactions between Allscripts and Netsmart during the periods presented have been eliminated in the supplemental pro forma data. The consolidated statement of operations for the three months ended March 31, 2016 does not include any actual revenue and earnings from Netsmart or HealthMEDX since these acquisitions were completed on April 19, 2016 and October 27, 2016, respectively. The below supplemental pro forma data for the combined entity is presented under the assumption that both of these acquisitions occurred on January 1, 2015: (In thousands, except per share amounts) Three Months Ended March 31, 2016 Supplemental pro forma data for combined entity: Revenue $ 401,334 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (14,996 ) Loss per share, basic and diluted $ (0.08 )

Fair Value Measurements and Inv

Fair Value Measurements and Investments	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Fair Value Measurements and Investments	3. Fair Value Measurements and Investments Fair value measurements are based upon observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our view of market participant assumptions in the absence of observable market information. We utilize valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. The fair values of assets and liabilities required to be measured at fair value are categorized based upon the level of judgment associated with the inputs used to measure their value in one of the following three categories: Level 1: Inputs are unadjusted quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2: Inputs, other than quoted prices included in Level 1, are observable for the asset or liability, either directly or indirectly. Our Level 2 derivative financial instruments include foreign currency forward contracts valued based upon observable values of spot and forward foreign currency exchange rates. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Level 3: Unobservable inputs that are significant to the fair value of the asset or liability, and include situations where there is little, if any, market activity for the asset or liability. Our Level 3 financial instruments include derivative financial instruments comprising the 1.25% Call Option asset and the 1.25% embedded cash conversion option liability that are not actively traded. These derivative instruments were designed with the intent that changes in their fair values would substantially offset, with limited net impact to our earnings. Therefore, we believe the sensitivity of changes in the unobservable inputs to the option pricing model for these instruments is substantially mitigated. Refer to Note 10, “Derivative Financial Instruments,” for further information regarding these derivative financial instruments. Our Level 3 financial instruments also include a third party non-marketable convertible note and Netsmart’s stock-based compensation liability. Refer to Note 4, “Stockholders’ Equity,” for further information regarding Netsmart’s stock-based compensation liability. The sensitivity of changes in the unobservable inputs to the valuation pricing model used to value these instruments is not material to our consolidated results of operations. The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 74,400 $ 0 $ 0 $ 74,400 $ 149,100 $ 0 $ 0 $ 149,100 Non-marketable convertible note Other assets 0 0 1,154 1,154 0 0 1,156 1,156 1.25% Call Option Other assets 0 0 34,685 34,685 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (35,562 ) (35,562 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 2,369 0 2,369 0 1,021 0 1,021 Fair value of stock-based compensation liability - Netsmart Accrued compensation and benefits 0 0 (2,205 ) (2,205 ) 0 0 (5,806 ) (5,806 ) Total $ 74,400 $ 2,369 $ (1,928 ) $ 74,841 $ 149,100 $ 1,021 $ (5,229 ) $ 144,892 Investments The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Investees Original Carrying Value at (In thousands) at March 31, 2017 Investment March 31, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 3,722 $ 2,436 Cost method investments 5 29,961 26,011 26,041 Total equity investments 8 $ 31,619 $ 29,733 $ 28,477 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of March 31, 2017, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital. Long-Term Financial Liabilities Our long-term financial liabilities include amounts outstanding under our senior secured credit facility and Netsmart’s Credit Agreements (as defined in Note 8, “Debt”), with carrying values that approximate fair value since the interest rates approximate current market rates. In addition, the carrying amount of our 1.25% Cash Convertible Senior Notes (the “1.25% Notes”) approximates fair value as March 31, 2017, since the effective interest rate on the 1.25% Notes approximates current market rates. See Note 8, “Debt,” for further information regarding our long-term financial liabilities.

Stockholders' Equity

Stockholders' Equity	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Shareholders' Equity	4. Stockholders' Equity Stock-based Compensation Expense Stock-based compensation expense recognized during the three months ended March 31, 2017 and 2016 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. In addition, the three months ended March 31, 2017 includes stock-based compensation expense related to Netsmart’s time-based liability classified option awards. No stock-based compensation costs were capitalized during the three months ended March 31, 2017 and 2016. Three Months Ended March 31, (In thousands) 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 1,125 $ 1,169 Client services 1,572 1,490 Total cost of revenue 2,697 2,659 Selling, general and administrative expenses 3,550 5,166 Research and development 2,589 2,576 Total stock-based compensation expense $ 8,836 $ 10,401 Allscripts Long-Term Incentive Plan We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved. The fair value of service-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three months ended March 31, 2017 and 2016. We granted stock-based awards as follows: Three Months Ended March 31, 2017 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,769 $ 12.41 Performance-based restricted stock units with a service condition 572 $ 11.93 Market-based restricted stock units with a service condition 572 $ 13.40 2,913 $ 12.51 During the three months ended March 31, 2017 and the year ended December 31, 2016, 1.0 million and 1.5 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards. Net Share-settlements Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the three months ended March 31, 2017 and year ended December 31, 2016 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the three months ended March 31, 2017 and 2016 were 494 thousand and 323 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting. Netsmart Stock-based Compensation Expense Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: (In thousands) Three Months Ended March 31, 2017 Cost of revenue: Software delivery, support and maintenance $ (35 ) Client services (81 ) Total cost of revenue (116 ) Selling, general and administrative expenses (3,337 ) Research and development (91 ) Total stock-based compensation expense (benefit) $ (3,544 ) At March 31, 2017, the liability for outstanding awards was $2.2 No option unit awards were granted by Netsmart during the three months ended March 31, 2017.

Earnings (Loss) Per Share

Earnings (Loss) Per Share	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Earnings (Loss) Per Share	5. Earnings (Loss) Per Share Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method. The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2017 2016 Basic (Loss) Earnings per Common Share: Net (loss) income $ (8,565 ) $ 2,127 Less: Net income attributable to non-controlling interests $ (453 ) $ (78 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ (10,962 ) $ 0 Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (19,980 ) $ 2,049 Weighted-average common shares outstanding 180,767 188,561 Basic (Loss) Earnings per Common Share $ (0.11 ) $ 0.01 Diluted (Loss) Earnings per Common Share: Net (loss) income $ (8,565 ) $ 2,127 Less: Net income attributable to non-controlling interests $ (453 ) $ (78 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ (10,962 ) $ 0 Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (19,980 ) $ 2,049 Weighted-average common shares outstanding 180,767 188,561 Dilutive effect of stock options, restricted stock unit awards and warrants 0 2,180 Weighted-average common shares outstanding assuming dilution 180,767 190,741 Diluted (Loss) Earnings per Common Share $ (0.11 ) $ 0.01 As a result of the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three months ended March 31, 2017, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for that period, since the inclusion of any stock equivalents would be anti-dilutive. The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,689 25,201

Goodwill and Intangible Assets

Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill and intangible assets consist of the following: March 31, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 627,902 $ (361,484 ) $ 266,418 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 813,288 (438,289 ) 374,999 813,021 (430,960 ) 382,061 Total $ 1,441,190 $ (799,773 ) $ 641,417 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,928,358 1,924,052 Total $ 2,007,358 $ 2,003,052 Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 Other additions 0 0 4,039 4,039 Foreign exchange translation 267 0 0 267 Balance as of March 31, 2017 $ 844,104 $ 404,875 $ 679,379 $ 1,928,358 There were no accumulated impairment losses associated with our goodwill as of March 31, 2017 or December 31, 2016. Other additions during the three months ended March 31, 2017 relate to goodwill arising from Netsmart’s Purchase Agreement with a third party and a $0.1 million measurement period adjustment related to the acquisition of HealthMEDX. Refer to Note 2, “Business Combinations,” for additional information regarding these transactions.

Asset Impairment Charges

Asset Impairment Charges	3 Months Ended
	Mar. 31, 2017
Asset Impairment Charges [Abstract]
Asset Impairment Charges	7. Asset Impairment Charges We incurred the following asset impairment charges: Three Months Ended March 31, (In thousands) 2017 2016 Asset impairment charges $ 0 $ 4,650 During the first quarter of 2016, we incurred non-cash asset impairment charges which included $2.2 million for the impairment of capitalized software as a result of our decision to discontinue several software development projects, $2.1 million for the impairment of one of our cost method equity investments, and other charges of $0.4 million to write down a long-term asset to its estimated net realizable value. There were no asset impairment charges during the first quarter of 2017.

Debt

Debt	3 Months Ended
	Mar. 31, 2017
Debt Disclosure [Abstract]
Debt	8. Debt Debt outstanding, excluding capital leases, consisted of the following: March 31, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 45,941 $ 299,059 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 436,250 4,356 431,894 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 431,837 11,178 420,659 432,925 11,655 421,270 Second Lien Term Loan 167,000 8,530 158,470 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,380,087 $ 70,005 $ 1,310,082 $ 1,386,813 $ 74,433 $ 1,312,380 Less: debt payable within one year - excluding Netsmart 18,750 473 18,277 15,638 480 15,158 Less: debt payable within one year - Netsmart 4,351 1,895 2,456 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,356,986 $ 67,637 $ 1,289,349 $ 1,366,824 $ 72,053 $ 1,294,771 Interest expense consisted of the following: Three Months Ended March 31, (In thousands) 2017 2016 Interest expense $ 4,834 $ 3,538 Amortization of discounts and debt issuance costs 3,581 3,431 Netsmart: Interest expense (1) 10,917 0 Amortization of discounts and debt issuance costs 848 0 Total interest expense $ 20,180 $ 6,969 (1) Includes interest expense related to capital leases. Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended March 31, (In thousands) 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,246 3,108 Total interest expense related to the 1.25% Notes $ 4,324 $ 4,186 Allscripts Senior Secured Credit Facility As of March 31, 2017, $231.3 million under a term loan, $205.0 million under our revolving credit facility, and $0.8 million in letters of credit were outstanding under our senior secured credit facility. As of March 31, 2017, the interest rate on the borrowings under our senior secured credit facility was LIBOR plus 2.00%, which totaled 2.98%. We were in compliance with all covenants under the senior secured credit facility agreement as of March 31, 2017. As of March 31, 2017, we had $344.2 million available, net of outstanding letters of credit, under our revolving credit facility. There can be no assurance that we will be able to draw on the full available balance of our revolving credit facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. As of March 31, 2017, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount. As of March 31, 2017, $431.8 million under the Netsmart First Lien Term Loan, $167.0 million under the Netsmart Second Lien Term Loan and $1.5 million in letters of credit under the Netsmart Revolving Facility were outstanding (collectively, the “Credit Agreements”). As of March 31, 2017, the interest rate on the borrowings under the Netsmart First Lien Term Loan was Adjusted LIBO plus 4.50%, which totaled 5.65%, and the Netsmart Revolving Facility was Adjusted LIBO plus 4.75%, which totaled 7.75%. As of March 31, 2017, the interest rate on the borrowings under the Netsmart Second Lien Term Loan was Adjusted LIBO plus 9.50%, which totaled 10.55%. Netsmart was in compliance with all covenants under its Credit Agreements as of March 31, 2017. As of March 31, 2017, Netsmart had $48.5 million available, net of outstanding letters of credit, under the Netsmart Revolving Facility. There can be no assurance that Netsmart will be able to draw on the full available balance of the Netsmart Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings. The following table summarizes our future payment obligations under our debt as of March 31, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 231,250 12,500 28,125 40,625 150,000 0 0 Revolving Facility (2) 205,000 0 0 0 205,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 431,837 3,263 4,351 4,351 4,351 4,351 411,170 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,380,087 $ 15,763 $ 32,476 $ 44,976 $ 704,351 $ 4,351 $ 578,170 (1) (2)

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Income Taxes	9. Income Taxes We account for income taxes under FASB Accounting Standards Codification 740, Income Taxes Three Months Ended March 31, (In thousands) 2017 2016 (Loss) income before income taxes $ (8,393 ) $ 2,690 Income tax provision $ (172 ) $ (563 ) Effective tax rate (2.0 %) 20.9 % Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate due primarily to valuation allowance, permanent differences, income attributable to foreign jurisdictions taxed at lower rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three months ended March 31, 2017, compared with the prior year comparable period, differs primarily due to the tax impact of foreign dividends recorded in the three months ended March 31, 2016. In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). Due to the level of forecasted operating income for the year ending December 31, 2017, applied to a pre-tax loss for the three months ended March 31, 2017, we recorded $2.4 million of valuation allowance during the three months ended March 31, 2017 related to deferred tax assets associated with net operating loss carryforwards. Effective January 1, 2017, we adopted ASU 2016-09. The guidance in ASU 2016-09, among other things, will require all income tax effects of share-based awards to be recognized in the statement of operations when the awards vest or are settled as a discrete item in the period in which they occur. In the three months ended March 31, 2017, we recorded $1.4 million of tax expense for awards in which the compensation cost recorded was higher than the tax deductions for the awards. We recorded an offsetting release of valuation allowance in the quarter of $1.4 million, the effect of which has already been included in the valuation allowance amount recorded in the three months ended March 31, 2017 noted above. ASU 2016-09 requires entities to recognize excess tax benefits, regardless of whether the tax deduction reduces taxes payable. As part of adopting the new standard, we recorded a gross cumulative effect adjustment of $5.6 million to the opening balance of retained earnings to create a deferred tax asset to recognize excess tax benefits not previously recorded. The net increase to retained earnings was $1.8 million due to the recognition of a corresponding valuation allowance of $3.8 million. Our unrecognized income tax benefits were $12.2 million and $11.4 million as of March 31, 2017 and December 31, 2016, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted in light of changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations, and changes in tax law.

Derivative Financial Instrument

Derivative Financial Instruments	3 Months Ended
	Mar. 31, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	10. Derivative Financial Instruments The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 2,369 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 34,685 N/A 1.25% Embedded cash conversion option N/A Other liabilities 35,562 Total derivatives $ 37,054 $ 35,562 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable Foreign Exchange Contracts We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties in order to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a decreasing percentage of forecasted monthly INR expenses over time. As of March 31, 2017, there were 21 forward contracts outstanding that were staggered to mature monthly starting in April 2017 and ending in June 2018. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond June 2018. As of March 31, 2017, the notional amounts of outstanding forward contracts ranged from 25 million to 120 million INR, or the equivalent of $0.4 million to $1.9 million, based on the exchange rate between the United States dollar and the INR in effect as of March 31, 2017. These amounts also approximate the ranges of forecasted future INR expenses we target to hedge in any one month in the future. The critical terms of the forward contracts and the related hedged forecasted future expenses matched and allowed us to designate the forward contracts as highly effective cash flow hedges. The effective portion of the change in fair value is initially recorded in accumulated other comprehensive loss (“AOCI”) and subsequently reclassified to income in the period in which the cash flows from the associated hedged transactions affect income. Any ineffective portion of the change in fair value of the cash flow hedges is recognized in current period income. During the three months ended March 31, 2017, no amount was excluded from the effectiveness assessment and no gains or losses were reclassified from AOCI into income as a result of forecasted transactions that failed to occur. As of March 31, 2017, we estimate that $2.1 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months. The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2017 Foreign exchange contracts $ 1,873 Cost of Revenue $ 178 Selling, general and administrative expenses 137 Research and development $ 210 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2016 Foreign exchange contracts $ 342 Cost of Revenue $ (31 ) Selling, general and administrative expenses (25 ) Research and development $ (43 ) 1.25% Call Option In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes. The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the 1.25% Call Option, refer to Note 3, “Fair Value Measurements and Investments.” The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal. 1.25% Notes Embedded Cash Conversion Option The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy. For further discussion of the inputs used to determine the fair value of the embedded cash conversion option, refer to Note 3, “Fair Value Measurements and Investments.” The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2017 2016 1.25% Call Option $ 17,605 $ (31,203 ) 1.25% Embedded cash conversion option (17,903 ) 31,393 Net gain (loss) included in other income, net $ (298 ) $ 190

Other Comprehensive Income

Other Comprehensive Income	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Other Comprehensive Income	11. Other Comprehensive Income Accumulated Other Comprehensive Loss Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities (1) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (2) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive (loss) income before reclassifications 1,515 (74,701 ) 1,146 (72,040 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 (320 ) (320 ) Net other comprehensive (loss) income 1,515 (74,701 ) 826 (72,360 ) Balance as of March 31, 2017 (3) $ (4,513 ) $ (131,121 ) $ 1,445 $ (134,189 ) (1) (2) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net losses on available for sale securities. (3) Net of taxes of $924 thousand for unrealized net gains on foreign exchange contract derivatives and $60 thousand for unrealized net losses on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive income before reclassifications 744 0 207 951 Net losses reclassified from accumulated other comprehensive loss 0 0 60 60 Net other comprehensive income 744 0 267 1,011 Balance as of March 31, 2016 (2) $ (3,756 ) $ 0 $ 525 $ (3,231 ) (1) (2) Net of taxes of $ Income Tax Effects Related to Components of Other Comprehensive Income (Loss) The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,515 $ 0 $ 1,515 $ 744 $ 0 $ 744 Available for sale securities: Net gain arising during the period (74,702 ) 1 (74,701 ) 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on available for sale securities (74,702 ) 1 (74,701 ) 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period 1,873 (727 ) 1,146 342 (135 ) 207 Net (gains) losses reclassified into income (525 ) 205 (320 ) 99 (39 ) 60 Net change in unrealized (losses) gains on foreign exchange contracts 1,348 (522 ) 826 441 (174 ) 267 Net (loss) gain on cash flow hedges 1,348 (522 ) 826 441 (174 ) 267 Other comprehensive (loss) income $ (71,839 ) $ (521 ) $ (72,360 ) $ 1,185 $ (174 ) $ 1,011

Contingencies

Contingencies	3 Months Ended
	Mar. 31, 2017
Commitments And Contingencies Disclosure [Abstract]
Contingencies	12. Contingencies In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated, certain of which are discussed below. We intend to vigorously defend ourselves in these matters. No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. If one or more of these legal proceedings were resolved against us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that reporting period could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients, which could further adversely affect our operating results. In the opinion of our management, based on the information currently available, there was not at least a reasonable possibility that we may have incurred any material loss, or any material loss in excess of a recorded accrual, with respect to the following matters. Our management will continue to evaluate the potential exposure related to these matters in future periods. On September 14, 2010, Pegasus Imaging Corporation filed a complaint against us in the Circuit Court of the Thirteenth Judicial Circuit of the State of Florida in and for Hillsborough County, Florida, which we transferred to the Special Superior Court for Complex Business Cases. The lawsuit also named former officers Jeffrey Amrein and John Reinhart as defendants. The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud and negligence. On June 27, 2013, we filed our First Amended Answer, Defenses, and Counterclaims to the plaintiff’s Second Amended Complaint, denying all material allegations, and asserting counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement and three counts of negligent misrepresentation. On July 7, 2014, the Court granted our motion for summary judgment on the plaintiff’s claim of unfair trade practices under Florida law and our motion for summary judgment as to the aforementioned defunct corporations, and granted the plaintiff’s motion for summary judgment on our counterclaims. In April 2017, the parties settled all of their remaining claims and agreed that the case will be dismissed without prejudice. On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff seeks $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional; and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. After plaintiff’s motion to compel arbitration of the counterclaims was granted, Allscripts made a demand in arbitration where the counterclaims remain pending. Discovery in the proposed class action has now concluded. On March 31, 2016, plaintiff filed its motion for class certification.

Business Segments

Business Segments	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Business Segments	13. Business Segments We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management. As of March 31, 2017, we had seven operating segments, which are aggregated into three reportable segments. The Clinical and Financial Solutions reportable segment includes the Ambulatory, Hospitals and Health Systems, previously named “Acute”, and the Payer and Life Sciences strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications and financial and information solutions, which primarily include electronic health record-related software, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Population Health reportable segment is comprised of three separate operating segments: Population Health, FollowMyHealth ® TM Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions on allocation of resources. With the exception of the Netsmart segment, in determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenues acquired in a business acquisition. With the exception of the Netsmart segment, we also exclude the amortization of intangible assets, stock-based compensation expense, non-recurring expenses and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Non-recurring expenses relate to certain severance, product consolidation, legal, consulting and other charges incurred in connection with activities that are considered one-time. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes corporate general and administrative expenses (including marketing expenses), which are centrally managed, as well as revenue and the associated cost from the resale of certain ancillary products, primarily hardware, other than the respective amounts associated with the Netsmart segment. The historical results of our Homecare TM Three Months Ended March 31, (In thousands) 2017 2016 Revenue: Clinical and Financial Solutions $ 280,455 $ 271,443 Population Health 59,062 55,055 Netsmart 73,007 0 Unallocated Amounts 951 19,060 Total revenue $ 413,475 $ 345,558 Gross Profit: Clinical and Financial Solutions $ 113,718 $ 114,021 Population Health 41,813 40,040 Netsmart 34,574 0 Unallocated Amounts (11,453 ) (2,163 ) Total gross profit $ 178,652 $ 151,898 Income (loss) from operations: Clinical and Financial Solutions $ 54,986 $ 60,838 Population Health 28,545 24,890 Netsmart 8,929 0 Unallocated Amounts (81,197 ) (73,832 ) Total income from operations $ 11,263 $ 11,896

Basis of Presentation and Sig20

Basis of Presentation and Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2017
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of and for the three months ended March 31, 2017 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting, although the Company believes that the disclosures made are adequate to make that information not misleading. These unaudited interim consolidated financial statements should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2016 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Significant Accounting Policies	Significant Accounting Policies There have been no changes to our significant accounting policies from those disclosed in our Form 10-K.
Recently Adopted Accounting Pronouncements and Accounting Pronouncements Not Yet Adopted	Recently Adopted Accounting Pronouncements In March 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update No. 2016-07, Investments – Equity Method and Joint Ventures (Topic 323): Simplifying the Transition to the Equity Method of Accounting In March 2016, the FASB issued Accounting Standards Update No. 2016-09, Compensation – Stock Compensation (Topic 718): Improvements to Share-Based Payment Accounting In August 2016, the FASB issued Accounting Standards Update No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments Accounting Pronouncements Not Yet Adopted In May 2014, the FASB issued Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 The new revenue recognition guidance permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the cumulative catch-up transition method). We currently plan to adopt the standard effective January 1, 2018 using the full retrospective method. We have completed our initial assessment of our systems, data and processes that will be affected by the implementation of this new guidance. We are continuing to work towards establishing policies, updating our processes and implementing necessary changes to be able to comply with the new requirements. Based on the results of our assessment to date, we anticipate this standard will have an impact, which could be significant, on our consolidated financial statements. While we are continuing to assess all potential impacts of the standard, we currently believe the most significant impact relates to our accounting for software license revenue. We expect revenue related to hardware, software-as-a-service-based offerings, professional services, electronic data interchange services, and managed services to remain substantially unchanged. We expect to recognize a significant portion of license revenue upfront rather than be restricted to payment amounts due under extended payment term contracts as required under the current guidance. We also expect to recognize license revenue upfront rather than over the subscription period from certain multi-year software subscriptions that include both software licenses and software maintenance. Due to the complexity of certain of our license subscription contracts, the actual revenue recognition treatment required under the standard will be dependent on contract-specific terms, and may vary in some instances from upfront recognition. In January 2017, the FASB issued Accounting Standards Update No. 2017-01, Business Combinations (Topic 805): Clarifying the Definition of a Business In January 2017, the FASB issued Accounting Standards Update No. 2017-04, Intangibles—Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, would have a material impact on our consolidated financial statements.

Business Combinations (Tables)

Business Combinations (Tables)	3 Months Ended
	Mar. 31, 2017
Business Combinations [Abstract]
Proforma Results	The consolidated statement of operations for the three months ended March 31, 2016 does not include any actual revenue and earnings from Netsmart or HealthMEDX since these acquisitions were completed on April 19, 2016 and October 27, 2016, respectively. The below supplemental pro forma data for the combined entity is presented under the assumption that both of these acquisitions occurred on January 1, 2015: (In thousands, except per share amounts) Three Months Ended March 31, 2016 Supplemental pro forma data for combined entity: Revenue $ 401,334 Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (14,996 ) Loss per share, basic and diluted $ (0.08 )

Fair Value Measurements and I22

Fair Value Measurements and Investments (Tables)	3 Months Ended
	Mar. 31, 2017
Fair Value Disclosures [Abstract]
Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates: Balance Sheet March 31, 2017 December 31, 2016 (In thousands) Classifications Level 1 Level 2 Level 3 Total Level 1 Level 2 Level 3 Total NantHealth Common Stock Available for sale marketable securities $ 74,400 $ 0 $ 0 $ 74,400 $ 149,100 $ 0 $ 0 $ 149,100 Non-marketable convertible note Other assets 0 0 1,154 1,154 0 0 1,156 1,156 1.25% Call Option Other assets 0 0 34,685 34,685 0 0 17,080 17,080 1.25% Embedded cash conversion option Other liabilities 0 0 (35,562 ) (35,562 ) 0 0 (17,659 ) (17,659 ) Foreign exchange derivative assets Prepaid expenses and other current assets 0 2,369 0 2,369 0 1,021 0 1,021 Fair value of stock-based compensation liability - Netsmart Accrued compensation and benefits 0 0 (2,205 ) (2,205 ) 0 0 (5,806 ) (5,806 ) Total $ 74,400 $ 2,369 $ (1,928 ) $ 74,841 $ 149,100 $ 1,021 $ (5,229 ) $ 144,892
Summary of Equity Investments Included in Other Assets	The following table summarizes our equity investments which are included in other assets in the accompanying consolidated balance sheet: Number of Investees Original Carrying Value at (In thousands) at March 31, 2017 Investment March 31, 2017 December 31, 2016 Equity method investments (1) 3 $ 1,658 $ 3,722 $ 2,436 Cost method investments 5 29,961 26,011 26,041 Total equity investments 8 $ 31,619 $ 29,733 $ 28,477 (1) Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag. As of March 31, 2017, it is not practicable to estimate the fair value of our non-marketable cost and equity method investments primarily because of their illiquidity and restricted marketability. The factors we considered in trying to determine fair value include, but are not limited to, available financial information, the issuer’s ability to meet its current obligations and the issuer’s subsequent or planned raises of capital.

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2017
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Three Months Ended March 31, (In thousands) 2017 2016 Cost of revenue: Software delivery, support and maintenance $ 1,125 $ 1,169 Client services 1,572 1,490 Total cost of revenue 2,697 2,659 Selling, general and administrative expenses 3,550 5,166 Research and development 2,589 2,576 Total stock-based compensation expense $ 8,836 $ 10,401
Stock-Based Awards Granted	We granted stock-based awards as follows: Three Months Ended March 31, 2017 Weighted-Average Grant Date (In thousands, except per share amounts) Shares Fair Value Service-based restricted stock units 1,769 $ 12.41 Performance-based restricted stock units with a service condition 572 $ 11.93 Market-based restricted stock units with a service condition 572 $ 13.40 2,913 $ 12.51
Netsmart [Member]
Capital Unit [Line Items]
Stock-Based Compensation Expense (Benefit)	Stock-based compensation expense (benefit) related to Netsmart’s time-based liability classified option awards was included in the following categories in our consolidated statements of operations: (In thousands) Three Months Ended March 31, 2017 Cost of revenue: Software delivery, support and maintenance $ (35 ) Client services (81 ) Total cost of revenue (116 ) Selling, general and administrative expenses (3,337 ) Research and development (91 ) Total stock-based compensation expense (benefit) $ (3,544 )

Earnings (Loss) Per Share (Tabl

Earnings (Loss) Per Share (Tables)	3 Months Ended
	Mar. 31, 2017
Earnings Per Share [Abstract]
Calculations of Earnings (Loss) Per Share	The calculations of earnings (loss) per share are as follows: Three Months Ended March 31, (In thousands, except per share amounts) 2017 2016 Basic (Loss) Earnings per Common Share: Net (loss) income $ (8,565 ) $ 2,127 Less: Net income attributable to non-controlling interests $ (453 ) $ (78 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ (10,962 ) $ 0 Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (19,980 ) $ 2,049 Weighted-average common shares outstanding 180,767 188,561 Basic (Loss) Earnings per Common Share $ (0.11 ) $ 0.01 Diluted (Loss) Earnings per Common Share: Net (loss) income $ (8,565 ) $ 2,127 Less: Net income attributable to non-controlling interests $ (453 ) $ (78 ) Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart $ (10,962 ) $ 0 Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders $ (19,980 ) $ 2,049 Weighted-average common shares outstanding 180,767 188,561 Dilutive effect of stock options, restricted stock unit awards and warrants 0 2,180 Weighted-average common shares outstanding assuming dilution 180,767 190,741 Diluted (Loss) Earnings per Common Share $ (0.11 ) $ 0.01
Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share	The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive: Three Months Ended March 31, (In thousands) 2017 2016 Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation 26,689 25,201

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	Goodwill and intangible assets consist of the following: March 31, 2017 December 31, 2016 Gross Gross Carrying Accumulated Intangible Carrying Accumulated Intangible (In thousands) Amount Amortization Assets, Net Amount Amortization Assets, Net Intangibles subject to amortization: Proprietary technology $ 627,902 $ (361,484 ) $ 266,418 $ 627,819 $ (347,477 ) $ 280,342 Customer contracts and relationships 813,288 (438,289 ) 374,999 813,021 (430,960 ) 382,061 Total $ 1,441,190 $ (799,773 ) $ 641,417 $ 1,440,840 $ (778,437 ) $ 662,403 Intangibles not subject to amortization: Registered trademarks $ 79,000 $ 79,000 Goodwill 1,928,358 1,924,052 Total $ 2,007,358 $ 2,003,052
Changes in Carrying Amount of Goodwill	Changes in the carrying amounts of goodwill by reportable segment for the three months ended March 31, 2017 were as follows: Clinical and Population (In thousands) Financial Solutions Health Netsmart Total Balance as of December 31, 2016 $ 843,837 $ 404,875 $ 675,340 $ 1,924,052 Other additions 0 0 4,039 4,039 Foreign exchange translation 267 0 0 267 Balance as of March 31, 2017 $ 844,104 $ 404,875 $ 679,379 $ 1,928,358

Asset Impairment Charges (Table

Asset Impairment Charges (Tables)	3 Months Ended
	Mar. 31, 2017
Asset Impairment Charges [Abstract]
Asset Impairment Charges	We incurred the following asset impairment charges: Three Months Ended March 31, (In thousands) 2017 2016 Asset impairment charges $ 0 $ 4,650

Debt (Tables)

Debt (Tables)	3 Months Ended
	Mar. 31, 2017
Debt Instrument [Line Items]
Debt Outstanding Excluding Capital Leases	Debt outstanding, excluding capital leases, consisted of the following: March 31, 2017 December 31, 2016 (In thousands) Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount Principal Balance Unamortized Discount and Debt Issuance Costs Net Carrying Amount 1.25% Cash Convertible Senior Notes $ 345,000 $ 45,941 $ 299,059 $ 345,000 $ 49,186 $ 295,814 Senior Secured Credit Facility 436,250 4,356 431,894 441,875 4,691 437,184 Netsmart Non-Recourse Debt: First Lien Term Loan 431,837 11,178 420,659 432,925 11,655 421,270 Second Lien Term Loan 167,000 8,530 158,470 167,000 8,901 158,099 Other debt 0 0 0 13 0 13 Total debt $ 1,380,087 $ 70,005 $ 1,310,082 $ 1,386,813 $ 74,433 $ 1,312,380 Less: debt payable within one year - excluding Netsmart 18,750 473 18,277 15,638 480 15,158 Less: debt payable within one year - Netsmart 4,351 1,895 2,456 4,351 1,900 2,451 Total long-term debt, less current maturities $ 1,356,986 $ 67,637 $ 1,289,349 $ 1,366,824 $ 72,053 $ 1,294,771
Interest Expense	Interest expense consisted of the following: Three Months Ended March 31, (In thousands) 2017 2016 Interest expense $ 4,834 $ 3,538 Amortization of discounts and debt issuance costs 3,581 3,431 Netsmart: Interest expense (1) 10,917 0 Amortization of discounts and debt issuance costs 848 0 Total interest expense $ 20,180 $ 6,969 (1) Includes interest expense related to capital leases.
Summary of Future Payment Obligations under Debt	The following table summarizes our future payment obligations under our debt as of March 31, 2017: (In thousands) Total Remainder of 2017 2018 2019 2020 2021 Thereafter 1.25% Cash Convertible Senior Notes (1) $ 345,000 $ 0 $ 0 $ 0 $ 345,000 $ 0 $ 0 Term Loan 231,250 12,500 28,125 40,625 150,000 0 0 Revolving Facility (2) 205,000 0 0 0 205,000 0 0 Netsmart Non-Recourse Debt (2) First Lien Term Loan 431,837 3,263 4,351 4,351 4,351 4,351 411,170 Second Lien Term Loan 167,000 0 0 0 0 0 167,000 Total debt $ 1,380,087 $ 15,763 $ 32,476 $ 44,976 $ 704,351 $ 4,351 $ 578,170 (1) (2)
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Interest Expense Related to 1.25% Notes	Interest expense related to the 1.25% Notes was comprised of the following: Three Months Ended March 31, (In thousands) 2017 2016 Coupon interest at 1.25% $ 1,078 $ 1,078 Amortization of discounts and debt issuance costs 3,246 3,108 Total interest expense related to the 1.25% Notes $ 4,324 $ 4,186

Income Taxes (Tables)

Income Taxes (Tables)	3 Months Ended
	Mar. 31, 2017
Income Tax Disclosure [Abstract]
Effective Tax Rates	Three Months Ended March 31, (In thousands) 2017 2016 (Loss) income before income taxes $ (8,393 ) $ 2,690 Income tax provision $ (172 ) $ (563 ) Effective tax rate (2.0 %) 20.9 %

Derivative Financial Instrume29

Derivative Financial Instruments (Tables)	3 Months Ended
	Mar. 31, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Fair Value and Balance Sheet Locations	The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates: March 31, 2017 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 2,369 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 34,685 N/A 1.25% Embedded cash conversion option N/A Other liabilities 35,562 Total derivatives $ 37,054 $ 35,562 December 31, 2016 Asset Derivatives Liability Derivatives (In thousands) Balance Sheet Location Fair Value Balance Sheet Location Fair Value Derivatives qualifying as cash flow hedges: Foreign exchange contracts Prepaid expenses and other current assets $ 1,021 Accrued expenses $ 0 Derivatives not subject to hedge accounting: 1.25% Call Option Other assets 17,080 N/A 1.25% Embedded cash conversion option N/A Other liabilities 17,659 Total derivatives $ 18,101 $ 17,659 N/A – We define “N/A” as disclosure not being applicable
Derivatives Instruments Designated as Cash Flow Hedges	The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss: Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2017 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2017 Foreign exchange contracts $ 1,873 Cost of Revenue $ 178 Selling, general and administrative expenses 137 Research and development $ 210 Amount of Gain (Loss) Recognized in OCI (Effective Portion) Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) (In thousands) Three Months Ended March 31, 2016 Location of Gain (Loss) Reclassified from AOCI into Income (Effective Portion) Three Months Ended March 31, 2016 Foreign exchange contracts $ 342 Cost of Revenue $ (31 ) Selling, general and administrative expenses (25 ) Research and development $ (43 )
Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option	The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations: Three Months Ended March 31, (In thousands) 2017 2016 1.25% Call Option $ 17,605 $ (31,203 ) 1.25% Embedded cash conversion option (17,903 ) 31,393 Net gain (loss) included in other income, net $ (298 ) $ 190

Other Comprehensive Income (Tab

Other Comprehensive Income (Tables)	3 Months Ended
	Mar. 31, 2017
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Losses on Available for Sale Securities (1) Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2016 (2) $ (6,028 ) $ (56,420 ) $ 619 $ (61,829 ) Other comprehensive (loss) income before reclassifications 1,515 (74,701 ) 1,146 (72,040 ) Net losses (gains) reclassified from accumulated other comprehensive loss 0 0 (320 ) (320 ) Net other comprehensive (loss) income 1,515 (74,701 ) 826 (72,360 ) Balance as of March 31, 2017 (3) $ (4,513 ) $ (131,121 ) $ 1,445 $ (134,189 ) (1) (2) Net of taxes of $402 thousand for unrealized net gains on foreign exchange contract derivatives and $61 thousand for unrealized net losses on available for sale securities. (3) Net of taxes of $924 thousand for unrealized net gains on foreign exchange contract derivatives and $60 thousand for unrealized net losses on available for sale securities. (In thousands) Foreign Currency Translation Adjustments Unrealized Net Gains (Losses) on Available for Sale Securities Unrealized Net Gains on Foreign Exchange Contracts Total Balance as of December 31, 2015 (1) $ (4,500 ) $ 0 $ 258 $ (4,242 ) Other comprehensive income before reclassifications 744 0 207 951 Net losses reclassified from accumulated other comprehensive loss 0 0 60 60 Net other comprehensive income 744 0 267 1,011 Balance as of March 31, 2016 (2) $ (3,756 ) $ 0 $ 525 $ (3,231 ) (1) (2) Net of taxes of $
Income Tax Effects Related to Components of Other Comprehensive Income (Loss)	The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”): Three Months Ended March 31, 2017 2016 (In thousands) Before-Tax Amount Tax Effect Net Amount Before-Tax Amount Tax Effect Net Amount Foreign currency translation adjustments $ 1,515 $ 0 $ 1,515 $ 744 $ 0 $ 744 Available for sale securities: Net gain arising during the period (74,702 ) 1 (74,701 ) 0 0 0 Net gain reclassified into income 0 0 0 0 0 0 Net change in unrealized losses on available for sale securities (74,702 ) 1 (74,701 ) 0 0 0 Derivatives qualifying as cash flow hedges: Foreign exchange contracts: Net (losses) gains arising during the period 1,873 (727 ) 1,146 342 (135 ) 207 Net (gains) losses reclassified into income (525 ) 205 (320 ) 99 (39 ) 60 Net change in unrealized (losses) gains on foreign exchange contracts 1,348 (522 ) 826 441 (174 ) 267 Net (loss) gain on cash flow hedges 1,348 (522 ) 826 441 (174 ) 267 Other comprehensive (loss) income $ (71,839 ) $ (521 ) $ (72,360 ) $ 1,185 $ (174 ) $ 1,011

Business Segments (Tables)

Business Segments (Tables)	3 Months Ended
	Mar. 31, 2017
Segment Reporting [Abstract]
Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts	Three Months Ended March 31, (In thousands) 2017 2016 Revenue: Clinical and Financial Solutions $ 280,455 $ 271,443 Population Health 59,062 55,055 Netsmart 73,007 0 Unallocated Amounts 951 19,060 Total revenue $ 413,475 $ 345,558 Gross Profit: Clinical and Financial Solutions $ 113,718 $ 114,021 Population Health 41,813 40,040 Netsmart 34,574 0 Unallocated Amounts (11,453 ) (2,163 ) Total gross profit $ 178,652 $ 151,898 Income (loss) from operations: Clinical and Financial Solutions $ 54,986 $ 60,838 Population Health 28,545 24,890 Netsmart 8,929 0 Unallocated Amounts (81,197 ) (73,832 ) Total income from operations $ 11,263 $ 11,896

Basis of Presentation and Sig32

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) $ in Millions	3 Months Ended
	Mar. 31, 2017USD ($)
ASU 2016-09 [Member]
Summary Of Significant Accounting Policy [Line Items]
Increase in retained earnings due to the recognition of excess tax benefit after valuation allowance	$ 1.8

Business Combinations - Additio

Business Combinations - Additional Information (Detail) - USD ($) $ in Millions	Oct. 27, 2016	Mar. 31, 2017
Business Acquisition [Line Items]
Contribution and investment agreement date		Mar. 20, 2016
Netsmart [Member]
Business Acquisition [Line Items]
Netsmart transaction completion date		Apr. 19, 2016
HealthMEDX, LLC [Member]
Business Acquisition [Line Items]
Date of acquisition	Oct. 27, 2016
Business combination, aggregate consideration	$ 39.2
Business combination, adjustment of fair value of liability		$ 0.1
Increase in goodwill from subsequent adjustment of liability		$ 0.1
Asset Purchase Agreement [Member]
Business Acquisition [Line Items]
Asset purchase agreement date		Mar. 31, 2017
Aggregate cash consideration to acquire intellectual property, certain contractual relationships and certain associates		$ 4

Pro forma Results (Detail)

Pro forma Results (Detail) - Combined Entity [Member] $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2016USD ($)$ / shares
Business Acquisition [Line Items]
Revenue	$ 401,334
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (14,996)
Loss per share, basic and diluted | $ / shares	$ (0.08)

Summary of Financial Assets and

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	$ 74,400	$ 149,100
Prepaid expenses and other current assets	108,157	102,551
Total	74,841	144,892
Fair Value of Stock-Based Compensation Liability - Netsmart [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued compensation and benefits	(2,205)	(5,806)
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	2,369	1,021
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(35,562)	(17,659)
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	34,685	17,080
Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	1,154	1,156
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	74,400	149,100
Total	74,400	149,100
Level 1 [Member] | Fair Value of Stock-Based Compensation Liability - Netsmart [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued compensation and benefits	0	0
Level 1 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 1 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	2,369	1,021
Level 2 [Member] | Fair Value of Stock-Based Compensation Liability - Netsmart [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued compensation and benefits	0	0
Level 2 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	2,369	1,021
Level 2 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 2 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Available for sale marketable securities	0	0
Total	(1,928)	(5,229)
Level 3 [Member] | Fair Value of Stock-Based Compensation Liability - Netsmart [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued compensation and benefits	(2,205)	(5,806)
Level 3 [Member] | Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] | 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	(35,562)	(17,659)
Level 3 [Member] | 1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	34,685	17,080
Level 3 [Member] | Non-marketable Convertible Note [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 1,154	$ 1,156

Summary of Equity Investments I

Summary of Equity Investments Included in Other Assets (Detail) $ in Thousands		3 Months Ended
		Mar. 31, 2017USD ($)Investment	Dec. 31, 2016USD ($)
Fair Value Disclosures [Abstract]
Equity method investments, Number of Investees | Investment	[1]	3
Cost method investments, Number of Investees | Investment		5
Total equity investments, Number of Investees | Investment		8
Equity method investments, Original Investment	[1]	$ 1,658
Cost method investments, Original Investment		29,961
Total equity investments, Original Investment		31,619
Equity method investments, Carrying Value		3,722	$ 2,436
Cost method investments, Carrying Value		26,011	26,041
Total equity investments, Carrying Value		$ 29,733	$ 28,477
[1]	Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.

Fair Value Measurements and I37

Fair Value Measurements and Investments - Additional Information (Detail)	Mar. 31, 2017
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2017	Mar. 31, 2016	Dec. 31, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0
Stock options granted	0	0
Share issued, exercise of options and release of stock awards	1,000,000		1,500,000
Shares settled for tax withholding	494,000	323,000
Netsmart [Member]
Class Of Stock [Line Items]
Liability for outstanding awards	$ 2,200,000
Estimated weighted average fair value, Black-Scholes-Merton option pricing model	$ 0.15		$ 1

Stock-Based Compensation Expens

Stock-Based Compensation Expense (Benefit) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	$ 8,836	$ 10,401
Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	(3,544)
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,697	2,659
Cost of revenue [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	(116)
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,125	1,169
Cost of revenue [Member] | Software delivery, Support and Maintenance [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	(35)
Cost of revenue [Member] | Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	1,572	1,490
Cost of revenue [Member] | Client services [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	(81)
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	3,550	5,166
Selling, General and Administrative Expenses [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	(3,337)
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation expense	2,589	$ 2,576
Research and development [Member] | Netsmart [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock based compensation benefit	$ (91)

Stock-Based Awards Granted (Det

Stock-Based Awards Granted (Detail) shares in Thousands	3 Months Ended
	Mar. 31, 2017$ / sharesshares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	2,913
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 12.51
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	1,769
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 12.41
Performance-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	572
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 11.93
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted | shares	572
Weighted-Average Grant Date Fair Value, granted | $ / shares	$ 13.40

Calculations of Earnings (Loss)

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Basic (Loss) Earnings per Common Share:
Net (loss) income	$ (8,565)	$ 2,127
Less: Net income attributable to non-controlling interests	(453)	(78)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	0
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (19,980)	$ 2,049
Weighted-average common shares outstanding	180,767	188,561
Basic (Loss) Earnings per Common Share	$ (0.11)	$ 0.01
Diluted (Loss) Earnings per Common Share:
Net (loss) income	$ (8,565)	$ 2,127
Less: Net income attributable to non-controlling interests	(453)	(78)
Less: Accretion of redemption preference on redeemable convertible non-controlling interest - Netsmart	(10,962)	0
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (19,980)	$ 2,049
Weighted-average common shares outstanding	180,767	188,561
Dilutive effect of stock options, restricted stock unit awards and warrants	0	2,180
Weighted-average common shares outstanding assuming dilution	180,767	190,741
Diluted (Loss) Earnings per Common Share	$ (0.11)	$ 0.01

Anti-Dilutive Stock Options, Re

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	26,689	25,201

Goodwill and Intangible Asset43

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,441,190	$ 1,440,840
Accumulated Amortization	(799,773)	(778,437)
Intangible Assets, Net	641,417	662,403
Registered trademarks	79,000	79,000
Goodwill	1,928,358	1,924,052
Total	2,007,358	2,003,052
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	627,902	627,819
Accumulated Amortization	(361,484)	(347,477)
Intangible Assets, Net	266,418	280,342
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	813,288	813,021
Accumulated Amortization	(438,289)	(430,960)
Intangible Assets, Net	$ 374,999	$ 382,061

Changes in Carrying Amount of G

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2017USD ($)
Goodwill [Line Items]
Goodwill	$ 1,924,052
Other additions	4,039
Foreign exchange translation	267
Goodwill, net	1,928,358
Clinical and Financial Solutions [Member]
Goodwill [Line Items]
Goodwill	843,837
Other additions	0
Foreign exchange translation	267
Goodwill, net	844,104
Population Health [Member]
Goodwill [Line Items]
Goodwill	404,875
Other additions	0
Foreign exchange translation	0
Goodwill, net	404,875
Netsmart [Member]
Goodwill [Line Items]
Goodwill	675,340
Other additions	4,039
Foreign exchange translation	0
Goodwill, net	$ 679,379

Goodwill and Intangible Asset45

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Schedule Of Goodwill And Intangible Assets [Line Items]
Accumulated impairment losses associated with goodwill	$ 0	$ 0
HealthMEDX, LLC [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Increase in goodwill from subsequent adjustment of liability	$ 100,000

Asset Impairment Charges (Detai

Asset Impairment Charges (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Asset Impairment Charges [Abstract]
Asset impairment charges	$ 0	$ 4,650

Asset Impairment Charges - Addi

Asset Impairment Charges - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Asset Impairment Charges [Line Items]
Asset impairment charges	$ 0	$ 4,650
Other charges		400
Capitalized Software Development Projects [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges		2,200
Cost Method Equity Investments [Member]
Asset Impairment Charges [Line Items]
Asset impairment charges		$ 2,100

Debt Outstanding Excluding Capi

Debt Outstanding Excluding Capital Leases (Detail) - USD ($) $ in Thousands	Mar. 31, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Principal Balance	$ 1,380,087		$ 1,386,813
Unamortized Discount and Debt Issuance Costs	70,005		74,433
Net Carrying Amount	1,310,082		1,312,380
Principal Balance, Current	18,750		15,638
Unamortized Discount and Debt Issuance Costs, Current	473		480
Net Carrying Amount, Current	18,277		15,158
Principal Balance, Noncurrent	1,356,986		1,366,824
Unamortized Discount and Debt Issuance Costs, Noncurrent	67,637		72,053
Net Carrying Amount, Noncurrent	1,289,349		1,294,771
Netsmart [Member]
Debt Instrument [Line Items]
Principal Balance, Current	4,351		4,351
Unamortized Discount and Debt Issuance Costs, Current	1,895		1,900
Net Carrying Amount, Current	2,456		2,451
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Principal Balance	345,000	[1]	345,000
Unamortized Discount and Debt Issuance Costs	45,941		49,186
Net Carrying Amount	299,059		295,814
Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Principal Balance	436,250		441,875
Unamortized Discount and Debt Issuance Costs	4,356		4,691
Net Carrying Amount	431,894		437,184
Netsmart Non-Recourse Debt First Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	431,837		432,925
Unamortized Discount and Debt Issuance Costs	11,178		11,655
Net Carrying Amount	420,659		421,270
Netsmart Non-Recourse Debt Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Principal Balance	167,000		167,000
Unamortized Discount and Debt Issuance Costs	8,530		8,901
Net Carrying Amount	158,470		158,099
Other Debt [Member]
Debt Instrument [Line Items]
Principal Balance	0		13
Unamortized Discount and Debt Issuance Costs	0		0
Net Carrying Amount	$ 0		$ 13
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail)

Interest Expense (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Total interest expense		$ 20,180	$ 6,969
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense		4,834	3,538
Amortization of discounts and debt issuance costs		3,581	3,431
Netsmart [Member]
Debt Instrument [Line Items]
Amortization of discounts and debt issuance costs		848	0
Interest expense	[1]	$ 10,917	$ 0
[1]	Includes interest expense related to capital leases.

Interest Expense Related to 1.2

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Cash Convertible Senior Notes [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078
Amortization of discounts and debt issuance costs	3,246	3,108
Total interest expense related to the 1.25% Notes	$ 4,324	$ 4,186

Debt - Additional Information (

Debt - Additional Information (Detail) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,380,087		$ 1,386,813
Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		7.75%
LIBOR Rate [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		4.75%
Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount	[1]	$ 231,250
Allscripts Senior Secured Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		205,000
Letters of credit outstanding		800
Credit facility, amount available		$ 344,200
Allscripts Senior Secured Revolving Facility [Member] | United States dollars [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		2.98%
Allscripts Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		2.00%
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 345,000	[2]	$ 345,000
Interest rate		1.25%
Netsmart First Lien Credit Agreement [Member] | Netsmart Revolving Facility [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 1,500
Credit facility, amount available		48,500
Netsmart First Lien Credit Agreement [Member] | Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 431,800
Netsmart Second Lien Credit Agreement [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate, effective percentage		10.55%
Netsmart Second Lien Credit Agreement [Member] | Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 167,000
Netsmart Second Lien Credit Agreement [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		9.50%
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Debt instrument principal amount		$ 431,837
Debt instrument, interest rate, effective percentage		5.65%
Netsmart First Lien Term Loan [Member] | LIBOR Rate [Member]
Debt Instrument [Line Items]
Debt instrument variable rate		4.50%
[1]	Assumes no additional borrowings after March 31, 2017 and that all drawn amounts are repaid upon maturity.
[2]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Payment Oblig

Summary of Future Payment Obligations under Debt (Detail) - USD ($) $ in Thousands		Mar. 31, 2017		Dec. 31, 2016
Debt Instrument [Line Items]
Total		$ 1,380,087		$ 1,386,813
Remainder of 2017		15,763
2,018		32,476
2,019		44,976
2,020		704,351
2,021		4,351
Thereafter		578,170
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Total		345,000	[1]	$ 345,000
Remainder of 2017	[1]	0
2,018	[1]	0
2,019	[1]	0
2,020	[1]	345,000
2,021	[1]	0
Thereafter	[1]	0
Term Loan [Member]
Debt Instrument [Line Items]
Total	[2]	231,250
Remainder of 2017	[2]	12,500
2,018	[2]	28,125
2,019	[2]	40,625
2,020	[2]	150,000
2,021	[2]	0
Thereafter	[2]	0
Netsmart First Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		431,837
Remainder of 2017		3,263
2,018		4,351
2,019		4,351
2,020		4,351
2,021		4,351
Thereafter		411,170
Netsmart Second Lien Term Loan [Member]
Debt Instrument [Line Items]
Total		167,000
Remainder of 2017		0
2,018		0
2,019		0
2,020		0
2,021		0
Thereafter		167,000
Revolving Facility [Member]
Debt Instrument [Line Items]
Total	[2]	205,000
Remainder of 2017	[2]	0
2,018	[2]	0
2,019	[2]	0
2,020	[2]	205,000
2,021	[2]	0
Thereafter	[2]	$ 0
[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.
[2]	Assumes no additional borrowings after March 31, 2017 and that all drawn amounts are repaid upon maturity.

Summary of Future Payment Obl53

Summary of Future Payment Obligations under Debt (Parenthetical) (Detail)	3 Months Ended
	Mar. 31, 2017
1.25% Cash Convertible Senior Notes [Member]
Debt Instrument [Line Items]
Notes maturity period	Jul. 1, 2020

Effective Tax Rates (Detail)

Effective Tax Rates (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Income Tax Disclosure [Abstract]
(Loss) income before income taxes	$ (8,393)	$ 2,690
Income tax provision	$ (172)	$ (563)
Effective tax rate	(2.00%)	20.90%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2017	Dec. 31, 2016
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Cumulative operating income loss period considered	3 years
Unrecognized income tax benefits	$ 12.2	$ 11.4
ASU 2016-09 [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Tax expense on compensation cost	1.4
Change in valuation allowance from offsetting release	(1.4)
Cumulative effect adjustment on retained earnings, gross	5.6
Increase in retained earnings due to the recognition of excess tax benefit after valuation allowance	1.8
Valuation allowance recognized	3.8
Valuation Allowance of Deferred Tax Assets [Member]
Income Loss From Operations Before Provision Benefit For Income Taxes [Line Items]
Valuation allowance related to deferred tax assets from operating loss carryforwards	$ 2.4

Fair Value and Balance Sheet Lo

Fair Value and Balance Sheet Locations - (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016
Derivatives Fair Value [Line Items]
Derivative asset, fair value	$ 37,054	$ 18,101
Derivative liability, fair value	35,562	17,659
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Prepaid Expenses and Other Current Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	2,369	1,021
Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Accrued expenses [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	0	0
Not Designated as Hedging Instrument [Member] | 1.25% Call Option [Member] | Other Assets [Member]
Derivatives Fair Value [Line Items]
Derivative asset, fair value	34,685	17,080
Not Designated as Hedging Instrument [Member] | 1.25% Embedded Cash Conversion Option [Member] | Other Liabilities [Member]
Derivatives Fair Value [Line Items]
Derivative liability, fair value	$ 35,562	$ 17,659

Derivative Financial Instrume57

Derivative Financial Instruments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017USD ($)Derivative	Mar. 31, 2017INR (₨)Derivative	Jun. 18, 2013USD ($)
1.25% Call Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
Foreign Exchange Forward Contracts [Member]
Derivative [Line Items]
Number of contracts | Derivative	21	21
Amount of Gain (Loss) Recognized in AOCI (Effective Portion)	$ 0
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	0
Unrealized derivatives gains (losses) included in other comprehensive (loss) income reclassified into income	$ 2,100,000
Estimated period of unrealized gains included in AOCI reclassified into income	12 months
Foreign Exchange Forward Contracts [Member] | Minimum [Member]
Derivative [Line Items]
Date of contracts mature	Apr. 30, 2017
Derivative notional amount outstanding	$ 400,000	₨ 25,000,000
Foreign Exchange Forward Contracts [Member] | Maximum [Member]
Derivative [Line Items]
Date of contracts mature	Jun. 30, 2018
Derivative notional amount outstanding	$ 1,900,000	₨ 120,000,000
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative [Line Items]
Debt instrument interest rate	1.25%	1.25%
1.25% Notes Embedded Cash Conversion Option [Member] | Level 3 [Member] | Fair Value Measurements, Recurring [Member]
Derivative [Line Items]
Fair value liability of embedded cash conversion option			$ 82,800,000

Derivatives Instruments Designa

Derivatives Instruments Designated as Cash Flow Hedges - (Detail) - Cash Flow Hedging [Member] - Foreign Exchange Contract [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Recognized in OCI (Effective Portion)	$ 1,873	$ 342
Cost of revenue [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	178	(31)
Selling, General and Administrative Expenses [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	137	(25)
Research and development [Member]
Derivative Instruments Gain Loss [Line Items]
Amount of Gain (Loss) Reclassified from AOCI into Income (Effective Portion)	$ 210	$ (43)

Net Impact of Changes in Fair V

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option - (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ (298)	$ 190
1.25% Call Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	17,605	(31,203)
1.25% Notes Embedded Cash Conversion Option [Member]
Derivative Instruments Gain Loss [Line Items]
Net gain (loss) included in other income, net	$ (17,903)	$ 31,393

Components of Accumulated Other

Components of Accumulated Other Comprehensive Loss (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	$ 1,232,466
Total other comprehensive (loss) income	(72,360)	$ 1,011
Balance at the end of the period	1,147,788
Foreign Currency Translation Adjustments [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(6,028)	(4,500)
Other comprehensive (loss) income before reclassifications	1,515	744
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive (loss) income	1,515	744
Balance at the end of the period	(4,513)	(3,756)
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(56,420)	0
Other comprehensive (loss) income before reclassifications	(74,701)	0
Net losses (gains) reclassified from accumulated other comprehensive loss	0	0
Total other comprehensive (loss) income	(74,701)	0
Balance at the end of the period	(131,121)	0
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	619	258
Other comprehensive (loss) income before reclassifications	1,146	207
Net losses (gains) reclassified from accumulated other comprehensive loss	(320)	60
Total other comprehensive (loss) income	826	267
Balance at the end of the period	1,445	525
Accumulated Other Comprehensive Income [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Balance at the beginning of the period	(61,829)	(4,242)
Other comprehensive (loss) income before reclassifications	(72,040)	951
Net losses (gains) reclassified from accumulated other comprehensive loss	(320)	60
Total other comprehensive (loss) income	(72,360)	1,011
Balance at the end of the period	$ (134,189)	$ (3,231)

Components of Accumulated Oth61

Components of Accumulated Other Comprehensive Loss (Parenthetical) (Detail) - USD ($) $ in Thousands	Mar. 31, 2017	Dec. 31, 2016	Mar. 31, 2016	Dec. 31, 2015
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 60	$ 61
Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Unrealized net gains (losses), taxes (benefits)	$ 924	$ 402	$ 340	$ 166

Income Tax Effects Related to C

Income Tax Effects Related to Components of Other Comprehensive Income (Loss) (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Accumulated Other Comprehensive Income Loss [Line Items]
Foreign currency translation adjustments, Before-Tax Amount	$ 1,515	$ 744
Net change in unrealized losses on available for sale securities, Before-Tax Amount	(74,702)	0
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	1,348	441
Other comprehensive (loss) income, Before-Tax Amount	(71,839)	1,185
Foreign currency translation adjustments, Tax Effect	0	0
Other comprehensive (loss) income, Tax Effect	(521)	(174)
Foreign currency translation adjustments, Net	1,515	744
Other comprehensive (loss) income, Net	(72,360)	1,011
Unrealized Net Gains (Losses) on Available for Sale Securities [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Available for sale securities, net gain arising during the period, Before-Tax Amount	(74,702)	0
Available for sale securities, net gain reclassified into income, Before-Tax Amount	0	0
Net change in unrealized losses on available for sale securities, Before-Tax Amount	(74,702)	0
Available for sale securities, net gain arising during the period, Tax Effect	1	0
Available for sale securities, net gain reclassified into income, Tax Effect	0	0
Net change in unrealized losses on available for sale securities, Tax Effect	1	0
Available for sale securities, net gain arising during the period, Net	(74,701)	0
Available for sale securities, net gain reclassified into income, Net	0	0
Net change in unrealized losses on available for sale securities, Net	(74,701)	0
Other comprehensive (loss) income, Net	(74,701)	0
Derivatives Qualifying as Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	1,348	441
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(522)	(174)
Derivatives qualifying as cash flow hedges, net gain (loss), Net	826	267
Derivatives Qualifying as Cash Flow Hedges [Member] | Foreign Exchange Contract [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Before-Tax Amount	1,873	342
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Before-Tax Amount	(525)	99
Derivatives qualifying as cash flow hedges, net gain (loss), Before-Tax Amount	1,348	441
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Tax Effect	(727)	(135)
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Tax Effect	205	(39)
Derivatives qualifying as cash flow hedges, net gain (loss), Tax Effect	(522)	(174)
Derivatives qualifying as cash flow hedges, net (losses) gains arising during the period, Net	1,146	207
Derivatives qualifying as cash flow hedges, net (gains) losses reclassified into income, Net	(320)	60
Derivatives qualifying as cash flow hedges, net gain (loss), Net	826	267
Other comprehensive (loss) income, Net	$ 826	$ 267

Contingencies - Additional Info

Contingencies - Additional Information (Detail) - Pending Litigation [Member] - $ / Violation	3 Months Ended
	Mar. 31, 2017	May 01, 2012
Pegasus Imaging Corporation [Member]
Loss Contingencies [Line Items]
Contingency allegations	The amended complaint added two defunct Florida corporations that did business with us, and asserted causes of action against defendants for fraudulent misrepresentations, negligent misrepresentations and deceptive and unfair trade practices under Florida law, allegedly arising from previous business dealings between the plaintiff and Advanced Imaging Concepts, Inc., a software company that we acquired in August 2003, and from our testing of a software development toolkit pursuant to a free trial license from the plaintiff in approximately 1999. On April 16, 2013, the plaintiff filed a Second Amended Complaint adding claims against us for breach of contract, fraud and negligence
Loss contingency action taken by defendant	Counterclaims against the plaintiff for breach of two license agreements, breach of warranty, breach of a settlement and arbitration agreement, and three counts of negligent misrepresentation.
Physicians Healthsource Inc [Member]
Loss Contingencies [Line Items]
Damages sought per alleged violation of the TCPA		500

Business Segments - Additional

Business Segments - Additional Information (Detail)	3 Months Ended
	Mar. 31, 2017Segment
Segment Reporting [Abstract]
Number of reportable segments	3
Number of operating segments	7

Revenues and Income from Operat

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2017	Mar. 31, 2016
Segment Reporting Information [Line Items]
Revenue	$ 413,475	$ 345,558
Gross Profit	178,652	151,898
Income from operations	11,263	11,896
Unallocated Amounts [Member]
Segment Reporting Information [Line Items]
Revenue	951	19,060
Gross Profit	(11,453)	(2,163)
Income from operations	(81,197)	(73,832)
Clinical and Financial Solutions [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	280,455	271,443
Gross Profit	113,718	114,021
Income from operations	54,986	60,838
Population Health [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	59,062	55,055
Gross Profit	41,813	40,040
Income from operations	28,545	24,890
Netsmart [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenue	73,007	0
Gross Profit	34,574	0
Income from operations	$ 8,929	$ 0